Sensex
73,319.55 profit arw 185.23 (0.25%)
Nifty
22,713.10 profit arw 33.70 (0.15%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 02-Apr-2026
Corporate News
02-Apr-2026     17:46

Emcure Pharmaceuticals reduces prices of its weight management drug Poviztra' in India

Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra' (semaglutide injection) across India.

The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses).

The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.

As the first Indian company to exclusively distribute and commercialise Poviztra', a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.

INDIAN INDICES

Sensex

73,319.55 185.23 (0.25%)

Nifty

22,713.10 33.70 (0.15%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,116.54 -177.50(-0.70%)